Genomic & Biopharma NewsKeytruda Better Than Chemotherapy for Untreated Advanced Merkel Cell Carcinomas, Phase 2 Trial Suggests
|Immuno-Oncology News, 2019-02-22 17:44:09|
Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
David Willoughby lives in Palm Beach Gardens and, until recently, worked there too. But the owner of Ocean Ridge Biosciences wanted to expand, and he couldn't find suitable space in northern Palm Beach County.
|ORB Company News, 2016-12-02 15:35:33|
One in 13 children affected by PTSD, according to landmark study
A new study has found that almost one in 13 young adults suffer from PTSD following a childhood trauma.
|News Medical Life Sciences, 2019-02-22 17:02:56|
'Holy herb' (Yerba santa) identified as a potential treatment for Alzheimer’s disease
Yerba santa, also known as the ‘Holy Herb’, may have important implications for patients with Alzheimer’s disease.
|News Medical Life Sciences, 2019-02-22 16:41:50|
The gene-edited twins born in China may have altered cognition and memory
A new study has fuelled further concerns over the controversial gene-editing experiment that was performed in China last year.
|News Medical Life Sciences, 2019-02-22 16:29:59|
Bioelectronics startup Neuspera nets $26M in two-tranche series B
Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants.
|Fierce Biotech, 2019-02-22 15:44:23|
AbbVie, Voyager add Parkinson’s disease, $65M to ‘vectorized’ antibody pact
A year after AbbVie and Voyager Therapeutics teamed up on Alzheimer’s disease, they are expanding their partnership to include Parkinson’s disease. Voyager picks up $65 million upfront and stands to reap a potential $245 million in preclinical and opt-in payments and an additional $728 million in milestones for each compound AbbVie chooses to take forward.
|Fierce Biotech, 2019-02-22 15:29:30|
NICE blames BioMarin for Brineura rejection after price talks break down
BioMarin and England’s cost-effectiveness gatekeeper have been negotiating for a year, but that hasn’t helped the rare-disease specialist secure reimbursement for its Batten disease drug Brineura.
|Fierce Pharma, 2019-02-22 14:57:04|
Electronic Sun Sentinel: Gene analysis lab moves to Deerfield Beach
|ORB Company News, 2016-12-02 21:24:27|
Takeda gout drug Uloric loses first-line approval after FDA confirms death risks
Takeda's gout drug Uloric just got pushed out of the first-line treatment club, thanks to a red flag on safety. After sifting postmarketing data, the FDA decided Uloric is riskier than its rival allopurinol and should be restricted to those who've tried the older drug without success.
|Fierce Pharma, 2019-02-22 14:46:45|
DOJ joins 5-year-old false claim and kickback suit against Abbott’s Alere acquisition
The legal headaches continue for Abbott following its 2017 roller-coaster acquisition of diagnostics maker Alere, with the U.S. Department of Justice signing on to a five-and-half-year-old whistleblower suit against one of Alere’s now-defunct subsidiaries over diabetic testing supplies and devices.
|Fierce Biotech, 2019-02-22 14:45:00|